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Abstract
Although metagenomics has been previously employed for pathogen discovery, its cost and complexity have prevented its
use as a practical front-line diagnostic for unknown infectious diseases. Here we demonstrate the utility of two
metagenomics-based strategies, a pan-viral microarray (Virochip) and deep sequencing, for the identification and
characterization of 2009 pandemic H1N1 influenza A virus. Using nasopharyngeal swabs collected during the earliest stages
of the pandemic in Mexico, Canada, and the United States (n=17), the Virochip was able to detect a novel virus most closely
related to swine influenza viruses without a priori information. Deep sequencing yielded reads corresponding to 2009 H1N1
influenza in each sample (percentage of aligned sequences corresponding to 2009 H1N1 ranging from 0.0011% to 10.9%),
with up to 97% coverage of the influenza genome in one sample. Detection of 2009 H1N1 by deep sequencing was possible
even at titers near the limits of detection for specific RT-PCR, and the percentage of sequence reads was linearly correlated
with virus titer. Deep sequencing also provided insights into the upper respiratory microbiota and host gene expression in
response to 2009 H1N1 infection. An unbiased analysis combining sequence data from all 17 outbreak samples revealed
that 90% of the 2009 H1N1 genome could be assembled de novo without the use of any reference sequence, including
assembly of several near full-length genomic segments. These results indicate that a streamlined metagenomics detection
strategy can potentially replace the multiple conventional diagnostic tests required to investigate an outbreak of a novel
pathogen, and provide a blueprint for comprehensive diagnosis of unexplained acute illnesses or outbreaks in clinical and
public health settings.
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Introduction
The 2009 H1N1 influenza A virus (2009 H1N1) is a novel
reassortant virus comprised of genomic segments originating from
swine, avian, and human influenza strains [1,2]. After the initial
identification of a swine-origin H1N1 by the CDC in April 2009,
the novel virus rapidly achieved sustained human-to-human
transmission worldwide, prompting a WHO declaration of a level
6 pandemic and rapid development of a vaccine [3]. As of August
6th, 2010, there have been at least 50 million cases and 18,449
confirmed deaths worldwide from the 2009 H1N1 pandemic
(http://www.who.int/csr/don/2010_08_06/en/index.html).
The emergence of 2009 H1N1 was marked by diagnostic
difficulties that hampered early efforts at detection. Rapid point-
of-care diagnostics were insensitive for diagnosing the novel virus,
and while existing molecular methods such as RT-PCR were able
to detect influenza, they could not differentiate 2009 H1N1 from
seasonal H3N2 or H1N1 infection [4]. Initial efforts to
characterize the virus relied on traditional Sanger sequencing
and the use of PCR primers to highly conserved regions in the
influenza genome, methods that would likely have failed had the
virus been more genetically divergent [1,2]. No clinical or
laboratory test was initially available to identify 2009 H1N1 with
high sensitivity and specificity, and the virus may have circulated
undetected in the human population for months [5]. Thus, there is
a clear need for the introduction of broad-range viral detection
methodologies into clinical and public health settings to deal with
emerging threats such as 2009 H1N1 influenza.
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13381Metagenomic approaches, including microarrays and deep
sequencing, have proven increasingly successful in recent years for
the diagnosis of infectious diseases by novel viral pathogens [6].
The Virochip is a pan-viral microarray that is designed to
simultaneously detect all known viruses [7,8]. Novel viral species
or strains can also be detected on the basis of conserved sequence
homology to known viruses, as demonstrated by the discovery of
the SARS coronavirus by Virochip in 2003 [9,10]. Other novel
viruses previously identified by Virochip include a new clade of
rhinoviruses [11], a human cardiovirus associated with respiratory
and diarrheal illness [12], and avian bornavirus, the etiologic agent
of outbreaks of proventricular dilation disease (PDD) in birds
[13,14]. For detection of known respiratory viruses, the Virochip
microarray was found to have a sensitivity and specificity
comparable to or superior to conventional diagnostic testing
[11,15]. Deep sequencing is a complementary approach capable of
detecting viruses that are too divergent from known viruses to be
detected by either PCR or microarray techniques
[16,17,18,19,20,21,22]; reviewed in [6]. De novo pyrosequencing
has enabled the discovery of two novel arenaviruses, an arenavirus
associated with a fatal cluster of cases in solid-organ transplant
patients (Dandenong virus) [22], and a hemorrhagic fever-
associated arenavirus from South Africa (Lujo virus) [21].
Metagenomic approaches are especially attractive in the study
of influenza given the constant threat of antigenic drift and shift
[23]. Microarrays can rapidly type the origins of different segments
to guard against the threat of novel reassortants and to detect co-
infections with other pathogens [8,15,24,25,26,27,28], while
pyrosequencing or the use of resequencing microarrays can
monitor the emergence of mutations that confer virulence or
resistance to antiviral drugs [29,30,31]. Deep sequencing strategies
have been recently employed to detect seasonal influenza viruses
in three clinical samples [32], as well as identify quasispecies of
2009 H1N1 in a single autopsy lung sample [33].
Here we analyzed a group of 17 early cases from the 2009
H1N1 pandemic from the United States (California), Canada, and
Mexico by Virochip and deep sequencing. We show that the
Virochip, in the absence of a priori information, was capable of
rapid characterization of 2009 H1N1 as an influenza A (H1N1)
virus most closely related to swine influenza viruses. We also
demonstrate the utility of deep sequencing of clinical samples to
identify and characterize not only the novel pathogen but also the
microbiota and host response to infection.
Results
Clinical data
Nasopharyngeal swab samples collected from 17 patients in
North America from April to June of 2009 were included in this
study (Table S1; Fig. 1A). Study patients were children or young
adults, 59% (10 of 17) male, with an average age of 22 years (range
1 to 41 years). Although the majority of cases (65%, 11 of 17) were
upper respiratory infections in the outpatient setting, 35% (7 of 17)
of patients were hospitalized for presumed H1N1 infection. All
three study patients from California were hospitalized in the
intensive care unit (ICU) with H1N1-associated pneumonia. Two
of the three California patients were pregnant women, a group
previously reported at high risk for severe complications from
H1N1 infection [34].
Virochip identification of 2009 H1N1
To determine whether a pan-viral microarray assay was capable
of identifying novel 2009 H1N1 in the absence of a priori sequence
information, we used the Virochip to comprehensively screen for
Figure 1. 2009 H1N1 sample collection, processing, and analysis. (A) Map of North America displaying originating locations for the 17
samples from laboratory-confirmed or suspected 2009 H1N1 cases analyzed in this study. The method for DNase treatment, found to greatly impact
the deep sequencing results, is also shown. (B) Pipeline for metagenomic analysis of deep sequencing data. Filtered high-quality reads are classified
by successive alignments to publicly available sequence databases.
doi:10.1371/journal.pone.0013381.g001
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influenza-like illness. Seventeen samples from Mexico (n=5),
Canada (n=9), and the United States (California) (n=3) were
suspected or PCR-confirmed cases of H1N1 infection. The
remaining control samples, all from California, were positive for
H1N1 seasonal influenza (n=2), H3N2 seasonal influenza (n=3),
another respiratory virus (n=6), or negative by all diagnostic
testing (n=1). Of note, the probes on the Virochip were designed
prior to the emergence of pandemic 2009 H1N1. Virochip
hybridization patterns corresponding to 15 of 17 samples
suspected or confirmed positive for 2009 H1N1 grouped together
by hierarchical cluster analysis, and were clearly distinguishable
from patterns corresponding to seasonal H3N2 influenza virus
(Fig. 2A). Two of the 17 samples, Mex-1225 and Mex-730,
exhibited very weak microarray probe intensities on Virochip
analysis and were grouped with the negative control samples. The
finding of weak Virochip intensities for these two samples was
reproducible, and likely secondary to low viral titers and/or high
background from host nucleic acid which can interfere with the
random PCR amplification step of Virochip analysis [8,15]. The
average normalized microarray intensities for the 2009 H1N1
samples were more pronounced with H1N1 probes derived from
swine influenza (A/swine/Wisconsin/464/98) than with probes
derived from human influenza (A/human/Puerto Rico/8/34); the
difference was statistically significant for 13 of 17 samples by t-test
analysis (Fig. 2B). Microarrays corresponding to seasonal H1N1
influenza displayed the opposite pattern, with H1N1 probes
derived from human influenza stronger in intensity than those
derived from swine influenza. Minimal cross-hybridization in
influenza A probes was observed with samples either negative or
harboring other respiratory viruses. The Virochip microarray was
also analyzed using Z-score analysis and E-Predict, an automated
method for viral species identification in microarrays [7,35]. Both
methods incorporate information from all of the oligonucleotide
probes on the Virochip simultaneously, including probes to the full
range of influenza strains, and revealed that a virus most similar to
swine influenza A (A/swine/Wisconsin/464/98) was present in
these samples (data not shown). Thus, the Virochip detected the
presence of a virus most closely related to swine influenza A/
H1N1 in samples from individuals infected with 2009 H1N1.
Metagenomics of 2009 H1N1 samples
To further characterize the metagenomics of 2009 H1N1 infection
in humans, we labeled the 17 influenza samples positive for 2009
H1N1 by Virochip with distinct molecular barcodes and analyzed
them by paired-end deep sequencing on three lanes of an Illumina
Genome Analyzer IIx. After trimming reads to remove barcodes and
exclude low-complexity or primer sequences, 11,427,212 high-quality
60-bp sequence reads were subjected to an iterative BLASTN analysis
pipeline (Fig. 1B). From the initial set of reads, a total of 9,819,120
(85.9%) reads were alignable (word size =11, E-value =1610
210 or
1610
25) to sequences obtained from the NCBI non-redundant
nucleotide (NT) database (March 2010 build).
The distribution of reads aligning to human, bacterial, and viral
sequences varied greatly depending upon the laboratory prepara-
tion method for the clinical sample prior to sequencing (Figure 3).
Samples from Mexico were not treated with DNase post-extraction,
resulting in most reads from those samples (75 to 98%) aligning to
human genomic DNA. In contrast, samples that were treated with
DNase post-extraction (United States and Canada) contained many
reads aligning to abundant, non-coding RNAs, including human
and bacterial ribosomal RNA (rRNA). Despite DNase treatment,
reads aligning to the human mitochondrial genome remained
abundant for several samples. The overall percentages of bacterial
(4.65%), viral (1.95%), other (1.02%) and nonaligning(14.1%) reads
were low, with some notable individual exceptions. Approximately
85% of reads from sample BC-59 aligned to bacterial sequences,
mostly corresponding to the Streptococcus genus. Two samples from
British Columbia had a disproportionately large number of reads
that aligned to viruses due to the addition of MS2 phage as an
internal positive control for the Luminex Respiratory Virus Panel
(RVP) assay (Luminex, Austin, TX).
Deep sequencing of bacteria
To determine if alterations in the upper respiratory tract
microbiome were present in samples from patients infected with
H1N1virus,wefurtheranalyzedthedeepsequencingreadsaligning
to bacteria. Interestingly, all bacterial reads aligned to rRNA
sequences, likely due to the high relative abundance of rRNA
transcripts in bacteria [36], and no bacterial mRNA reads were
observed.Giventhehigh degreeofconservationofrRNA sequences
in bacteria, each read could only be unambiguously classified at the
genus level (or at the family level in the case of Enterobactericeae)
(Fig. 4). In general, a high level of diversity of bacterial families was
observed in different samples, reflecting the known diversity of
bacterial flora in the nasopharynx [37]. Reads to the top three
bacterial families comprised anywhere from 22 to 97% of all
bacterial reads, depending on the sample (Fig. 4A). Moraxellaceae or
Enterobactericeae were the most common bacterial families found,
accounting for one of the three most common bacterial families in
14 of 17 samples (Fig. 4B). Significant numbers of reads aligning to
the Streptococcus genus were only seen in 5 of 17 samples, while reads
to unculturable agents (‘‘environmental samples’’) accounted for
between 1 to 48% of sequences aligning to bacteria.
Deep sequencing of 2009 H1N1 influenza and other
viruses
The majority of viral reads (n=122,487, 55.1%) aligned to
members of the Orthomyxoviridae (influenza) family (Table 1). Phages
comprised the second most common group of viruses, including
known controls (e.g. MS2 control phages), trace reagent contam-
inants (e.g. bacteriophage M13), and environmental phages. Reads
aligning to plant viruses were observed in two samples (BC-76 and
Mex-1225). Sixteen reads to murine leukemia viruses (MLVs) were
detected in 4 of 17 samples. In general, these MLV reads aligned
slightly better to Moloney murine leukemia virus (MMLV) than to
the recently described human xenotropic murine leukemia-related
virus (XMRV) [38,39,40], although, for some reads, the alignments
were identical. Interestingly, a single overlapping 97-nt paired-end
read from BC-22 aligned with 98% identity to a filovirus, Ebola-
Sudan (97% query coverage, E-value =9610
239) and mapped to a
gene coding for the Ebola viral glycoprotein. This BC-22 read also
aligned to other filoviruses (69–98% identity) but did not align to
any other viral family. We were able to reproduce detection of this
single filovirus read by specific RT-PCR, but, despite the use of
multiple sets of primers, we were unable to recover additional
filovirus sequence from this sample (data not shown). Aside from
influenza, the only other respiratory viral pathogen detected was
human adenovirus 4 in one Canadian sample (BC-22, 26 reads).
Influenza reads aligning to Orthomyxoviridae were found in all
specimens, ranging from 6 to 53,671 reads, or 0.00011% to 10.9%
of all aligning reads. After stratifying by originating location and
corresponding method of sample processing (pre-DNase and/or
post-DNase treatment), the percentage of total reads aligning to
influenza was linearly correlated with calculated viral titers by real-
time quantitative RT-PCR for sites in the United States
(California) and Canada but not in Mexico (Fig. 5A). Treatment
with DNase twice yielded the best percentage recovery of
Metagenomics of 2009 H1N1 Flu
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13381Figure 2. Virochip microarray analysis of samples from patients with influenza-like illness. (A) Cluster analysis and heat map profile for 29
nasopharyngeal swab samples analyzed using the Virochip. Samples (y-axis) and probes on the Virochip designed a priori and derived from 3
influenza A strains (x-axis) are clustered using hierarchical clustering. The red color saturation indicates the magnitude of normalized probe intensity.
(B) For each sample, the average normalized probe intensity for Virochip probes corresponding to human H1N1 influenza A (light blue) or swine
H1N1 influenza A (dark blue) is shown. The asterisks denote samples for which the difference in probe intensity is significant by t-test analysis
(p,0.05). Abbreviations: HA, hemagglutinin; NP, nucleoprotein; Cal, California; HRV, human rhinovirus; HPIV1, human parainfluenza virus 1; HCoV,
human coronavirus; HPIV3, human parainfluenza virus 3; RSV, respiratory syncytial virus; Neg, negative.
doi:10.1371/journal.pone.0013381.g002
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though only three samples were treated as such. The two samples
with the lowest viral titers (quantified based on RNA genome copy
equivalents) were Cal-UC12 and BC-59, with 71 and 17 copies
per RT-PCR reaction corresponding to 1.82610
4 and 4.74610
3
copies per mL of nasal swab sample, respectively (Fig. 5B).
However, despite very low viral titers, H1N1 influenza was still
detectable by deep sequencing, with 270 and 18 reads aligning to
influenza for Cal-UC12 and BC-59, respectively (Table 1).
Influenza reads from all 8 segments were found in 7 of 17
samples, while reads from at least two different segments were
found in every sample (Fig. 6; Figs. S1 and S2). Interestingly, reads
to the NS (nonstructural) segment were significantly less likely to
be found than reads to other segments (p,0.001 by Chi-square
analysis), with NS reads detected in only 8 of 17 samples. In
contrast, reads to PB2 were found in all 17 samples. Samples from
Mexico had the worst overall coverage, likely due to the high
percentage of human genomic background sequences as a result of
not treating samples with DNase post-extraction. In the sample
with the best overall coverage (BC-22), 97.0% of the 2009 H1N1
genome had at least 1x coverage, while 91.5% of the genome had
at least 3x coverage.
Sanger sequencing of 2009 H1N1 and analysis of single
nucleotide polymorphisms (SNPs)
We sought to assess the accuracy of deep sequencing relative to
traditional Sanger sequencing as well as search for single
nucleotide polymorphisms (SNPs) in the assembled deep sequenc-
ing reads that may represent heterogeneous populations of
influenza. Deep sequencing reads from the two samples in the
study with the highest coverage of the 2009 H1N1 genome, BC-22
(97.1% coverage at 1X) and Cal-UC2 (92.6% coverage at 1X),
were mapped to their full-genome scaffolds obtained by Sanger
sequencing. Overall, there was a high degree of concordance
(.99.9%) with deep sequencing and traditional Sanger sequencing
for both BC-22 and Cal-UC2 (Table S2).
Next, to identify potential mutations at key sites in the genome
that mediate drug resistance and virulence, we compared the
genomes of BC-22 and Cal-UC2 with the full-genome reference
sequence A/California/06/2009(H1N1) (Table S2). In total,
there were 30 nonambiguous nucleotide differences between
BC-22 and the original California strain and 39 nonambiguous
nucleotide differences between Cal-UC2 and the original strain,
of which 80% and 85% were detected by Sanger sequencing and
77% and 72% by deep sequencing alone, respectively. These
nucleotide differences corresponded to 12 and 18 nonsynon-
ymous mutations in the BC-22 and Cal-UC2 genomes,
respectively. The genome segment with the most amino acid
changes was the HA gene (27 of 69 nucleotide differences, or
39.1%). For both BC-22 and Cal-UC2, there were no differences
from the reference sequence A/California/06/2009(H1N1) at
key sites in the genome corresponding to known mutations
for antiviral resistance, enhanced transmission, or increased
virulence.
Figure 3. Metagenomic analysis of 2009 H1N1 samples by deep sequencing. Pie charts depicting the number and distribution of sequence
reads for each sample. Deep sequencing reads were successively aligned to human rRNA (dark green), human mitochondrial genomic DNA (medium
green), other human genomic DNA/transcriptomic RNA (light green), and the non-redundant nucleotide (NT) database, containing bacterial (blue),
viral (red), and ‘‘other’’ (black) sequences. Reads designated as ‘‘other’’ consisted solely of artificial plasmids or environmental sequences.
doi:10.1371/journal.pone.0013381.g003
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Although samples were prepared principally for the purposes of
metagenomics and the detection of known or novel pathogens,
treatment with DNase post-extraction to discriminate host mRNA
from genomic DNA enabled analysis of the transcriptomics of
2009 H1N1 infection in 12 of the 17 nasopharyngeal swab
samples. Deep sequencing reads aligning to the RefSeq RNA
database in these 12 samples were considered to arise from mRNA
transcripts. Since no RNA-seq data corresponding to nasopharyn-
geal samples from healthy individuals can be found in the NCBI
Sequence Read Archive (http://www.ncbi.nlm.inh.gov/sra), we
used a set of nasopharyngeal swab samples collected from 11
Kleine-Levin Syndrome (KLS) patients with influenza-like illness
but testing negative for influenza as background controls. Genes
Figure 4. Deep sequencing analysis of bacteria in 2009 H1N1 samples. All bacterial reads aligned to bacterial rRNA and are classified only at
the genus level (family level for Enterobactericeae). (A) The pie charts depict the proportion of bacterial rRNA reads corresponding to the top-ranking
(dark blue), second-ranking (medium blue), and third-ranking (light blue) bacterial families, as well as other remaining families (grey) and unidentified
environmental samples (black). (B) For each sample, the identities of the top-ranking, second-ranking, and third-ranking bacterial family, as well as
the majority genus within each family, are shown.
doi:10.1371/journal.pone.0013381.g004
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regulated (p,0.05) in four of the 12 influenza samples as compared
to the control samples, and from two study sites with different
specimen processing protocols (Fig. 7A). The interferon-related
genes that were preferentially up-regulated in 2009 H1N1 samples
relative to controls coded for chemokine ligands, 29-59 oligoadeny-
lated synthetases, IFN-inducible proteins, and STAT proteins,
proteins previously shown to play essential roles in the interferon-
mediated host immune response to viral infection [41]. Up-
regulation of interferon and immunity genes was seen in the four
samples with the highest 1X coverage of the influenza genome but
not necessarilyin samples witha high numberof totaltranscriptome
reads (Fig. 7B). Genes associated with cell structure and motility as
well as protein metabolism and intracellular protein trafficking were
also upregulated in 2009 H1N1 samples relative to control samples
(Fig. 7A).
De novo assembly of 2009 H1N1
We hypothesized that the unprecedented depth of coverage
obtainable by deep sequencing could enable detection and even de
novo assembly of novel viral pathogens in the absence of any
reference genome. To demonstrate the feasibility of this approach
in elucidating the cause of outbreaks from hitherto novel or
unknown viruses, we generated a modified NT database from
which all sequences corresponding to the Orthomyxoviridae family
had been removed (Fig. 8A). Pure de novo assemblies of paired-end
reads pooled from all 17 2009 H1N1 samples which did not align
to the modified NT database were then constructed using
Geneious software (Geneious, Auckland, NZ). Of the 582 final
contigs (contiguous sequences) of length greater than 100 bp
generated from the de novo assembly, 21 contigs mapped onto a
reference sequence of 2009 H1N1 influenza, with an N50 contig
size of 1,167 bp and coverage of 89.5% of the genome (Fig. 8B).
The four longest contigs all corresponded to 2009 H1N1 and
included the nearly full-length sequences of the PB1 (polymerase),
NP (nucleoprotein) and NA (neuraminidase) segments (Fig. 8C). A
cursory analysis of the remaining 561 contigs that did not map to
the influenza genome revealed that ,90% of these sequences were
low-complexity sequencing artifacts. From a similar analysis
performed on the best single sample (BC-22), de novo assembly of
90.3% of the genome was possible. No misassemblies were
observed even though the percentage of Orthomyxoviridae reads from
all 17 H1N1 samples or BC-22 alone comprised only 7.6% or
2.6% of the corresponding unaligned reads to the modified NT
database, respectively.
Discussion
In this study, we demonstrate the utility of a metagenomics-
based strategy combining a rapid, broad-spectrum diagnostic assay
(the Virochip microarray) with comprehensive deep sequencing to
identify and characterize a novel outbreak pathogen, using
pandemic 2009 H1N1 influenza as a case example. The Virochip
was capable of differentiating seasonal H3N2 and H1N1 influenza
from the novel 2009 pandemic strain by the use of multiple probes
designed a priori, and accurately characterized the novel virus as
closely related to swine influenza viruses. Complementary deep
sequencing of 17 clinical samples collected early in the course of
the 2009 H1N1 pandemic enabled detection of reads to the novel
strain in every sample, as well as de novo assembly of ,90% of the
genome amidst an enormous background of unaligned sequence
reads. As with the SARS coronavirus, the lack of a broad-based
Table 1. Distribution of viral reads in 2009 H1N1 influenza samples.
SAMPLE
TOTAL
ALIGNED
READS
TOTAL
VIRAL
READS FLU
% FLU
(TOTAL
ALIGNED READS)
% FLU
(VIRAL
READS) PHAGE MLV OTHER VIRAL
Ont-61 574,838 2,649 2,649 0.46% 100% - - -
Ont-69 25,500 2,243 2,243 8.8% 100% - - -
Ont-84 947,111 884 884 0.091% 100% - - -
Ont-MT1 578,886 18,079 18,079 3.1% 100% - - -
Ont-MT2 541,022 8,594 8,594 1.6% 100% - - -
BC-22 133,568 35,374 6,036 4.5% 17.1% 29,337 - 1 baculovirus
BC-44 143,907 67,448 1,824 1.3% 2.7% 65,624 - -
BC-59 110,049 2,751 18 0.016% 0.65% 2,730 - 3 HERV
BC-76 148,434 4,871 4,835 3.3% 99.3% 6 - 26 adenovirus type 4; 2 ebola
virus; 2 sweet potato chlorotic
stunt virus
Mex-619 1,972,432 1,050 938 0.048% 89.3% 111 1 -
Mex-730 86,070 81 78 0.091% 96.3% 3 - -
Mex-943 466,334 433 415 0.089% 95.8% 16 2 -
Mex-956 193,452 19 6 0.0031% 31.6% 5 - 8 HERV
Mex-1225 905,314 21 10 0.0011% 47.6% 10 - 1 iridovirus (rice virus)
Cal-UC2 747,965 54,081 53,671 7.2% 99.2% 393 5 12 baculovirus
Cal-UC6 201,808 23,516 21,937 10.9% 93.3% 1,571 8 -
Cal-UC12 2,042,430 274 270 0.013% 98.5% 4 - -
TOTAL 9,819,120 222,368 122,487 1.2% 55.1% 99,810 16 55
Abbreviations: Orthomyxo, orthomyxovirus; MLV, murine leukemia virus; HERV, human endogenous retrovirus.
doi:10.1371/journal.pone.0013381.t001
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contributed to the delayed identification of 2009 H1N1 as the
cause of an initial outbreak of influenza-like illness in Mexico. Our
approach – using the Virochip microarray for rapid screening and
deep sequencing for de novo assembly and more detailed
characterization – is robust, comprehensive, and directly applica-
ble for the investigation of future outbreaks from novel viral
pathogens, especially those which do not grow in culture.
Nearly all previous studies of metagenomic sequencing of viruses
from human clinical material for detection and discovery have
employed pyrosequencing [6,16,17,18,19,20,21,22,32,42,43]. The
longer reads from pyrosequencing (250–450 bp) facilitate the
assembly of individual reads into contigs, which assists in the
classification of reads by homology-based BLAST alignments. Our
results suggest, for example, that longer-read sequencing methods
such as pyrosequencing may be better suited than Illumina
sequencing for identification of bacteria. Accurate discrimination
of bacteria at the species (or even genus) level was not possible with
short 60-bp Illumina reads (Fig. 4B), as rRNA sequences
corresponding to related bacteria were found to be essentially
Figure 5. Relationship between percentage of deep sequencing reads aligning to 2009 H1N1 and viral titer. (A) For each sample, the
percentage of deep sequencing reads aligning to 2009 H1N1 is plotted as a function of the calculated viral titer (genome copy equivalents) per mL of
nasal swab sample, and a linear regression line is fitted to the data. Samples are stratified by originating location and method of DNase treatment. (B)
For each of the 17 samples, the calculated 2009 H1N1 viral titer (genome copy equivalents) per RT-PCR reaction (dark red) or per mL of nasal swab
sample (pink) is shown.
doi:10.1371/journal.pone.0013381.g005
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short Illumina reads aligning to bacterial rRNA into longer, more
easily identifiable contigs given the known presence of multiple
related bacterial species in the nasopharynx and the very high (and
likely) risk of producing misassemblies. On the other hand, a key
advantage of Illumina sequencing is the significant increase in read
depth (,100-fold) relative to pyrosequencing. The greater depth of
sequencing provides better and more accurate genome coverage as
well as increased capability to multiplex clinical samples.
In our study of 2009 H1N1 influenza by deep sequencing,
Illumina read lengths of 60 bp were sufficiently long to accurately
classify the vast majority of individual reads, thus making de novo
contig assembly prior to alignment unnecessary. In addition, we
were limited by the computational resources required for de novo
assembly of ,11.5 million sequences in a reasonable amount of
time. Our results demonstrate that a computational pipeline
consisting of sequential alignments of individual reads using high-
stringency cutoffs (Fig. 1), followed by de novo assembly of the
remaining unaligned reads and detailed analysis of the resulting
contigs(Fig.8),isanefficientstrategyforanalyzingthelargedatasets
generated by Illumina sequencing of clinical samples and for
pathogen discovery. In particular, the final de novo assembly step is
critical in identifying divergent sequences that may correspond to
novel pathogens. The assembly of longer contigs also eases the
burden of computationally intensive amino acid comparison
algorithms such as BLASTX, TBLASTX and PHI-BLAST by
reducing the number of sequences that need to be analyzed.
Although the costs of deep sequencing (,$200-$1000 USD/
sample) are still much greater than the reagent costs for diagnostic
RT-PCR assays (,$10 USD), deep sequencing is able to generate
much more useful information including data on the microbiome
and host gene expression as well as whole-genome sequencing of
pathogens which would require, for example, at least $1,200 USD
per influenza genome via traditional methods. In addition,
unbiased deep sequencing allows broad-based detection of novel
viruses that may elude diagnosis by specific RT-PCR assays. With
paired-end read lengths achievable on the Illumina platform now
approaching 300 bp, the use of deep sequencing for identification
Figure 6. Coverage map of the influenza genome for four 2009 H1N1 samples. For each originating location, the sample that was found to
have the best coverage is shown. The coverage is plotted on a log scale as a function of nucleotide position. For each segment, the coverage
percentages at 1X and 3X are indicated.
doi:10.1371/journal.pone.0013381.g006
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becomes feasible.
The number of reads corresponding to 2009 H1N1 and the
ability to map sequences onto the genome were highly dependent
on the method of sample preparation. The fewest viral reads were
detected in the five samples from Mexico that were not treated
with DNase after nucleic acid extraction. These samples contained
the highest percentage of human genomic sequence, with over
90% of sequences aligning to the human genome, as well as the
fewest reads to bacteria. Nakamura et al. also found .90% host
genomic material in nasopharyngeal aspirates from influenza-
infected individuals, and detected a similarly low percentage of
Figure 7. Deep sequencing analysis of the human transcriptome in 2009 H1N1 samples. Transcriptomic analysis was performed on the 12
samples that were treated with DNAse post-extraction. (A) Overexpressed genes in 2009 H1N1 samples relative to control samples were categorized
using the PANTHER database [52]. The six samples (out of 12) containing categories that are significantly overrepresented (p,0.05) are displayed.
Categories related to immunity and host defense are highlighted in red. (B) Bar graph showing the total reads aligning to the transcriptome (green)
and percentage coverage of the 2009 H1N1 genome by deep sequencing (red).
doi:10.1371/journal.pone.0013381.g007
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bacterial and cellular material [32]. Our data indicate that one of
the most important steps in viral detection by deep sequencing
may be the removal of host genomic DNA by post-extraction
treatment with DNase – a relatively straightforward procedure for
most clinical laboratories.
Figure 8. De novo assembly of the 2009 H1N1 genome. (A) Algorithm for de novo assembly of the 2009 H1N1 genome assuming no a priori
knowledge of the Orthomyxoviridae family and thus, no available reference genome. (B) Plot of number of contigs vs. contig length for de novo
assembled contigs mapping to 2009 H1N1 influenza derived from all 17 pooled samples (dark red) or sample BC-1422 alone (pink), as well as for
unaligned contigs (black). Note that the longest contigs all map to 2009 H1N1, even though influenza reads in all 17 pooled samples or BC-1422
comprise only 7.6% or 2.6% of the total reads, respectively. (C) Coverage of the 2009 H1N1 genome by de novo contig assembly from reads
corresponding to all 17 pooled samples (top, dark red lines) or BC-1422 alone (bottom, pink lines).
doi:10.1371/journal.pone.0013381.g008
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(with the observation of residual DNA mitochondrial reads in
several samples), it is true that additional pre-processing by
filtration, ultracentrifugation, or density-gradient purification
would likely have resulted in even better enrichment of viral
sequences [6]. However, for this metagenomics study, we sought to
mimic as closely as possible a clinical/public health laboratory
setting, and such enrichment strategies may be labor-intensive and
neither conducive to the demands of clinical laboratories nor
practical given the limited amount of clinical sample available. In
addition, an important drawback of directed viral purification
methods is that by biasing the sample towards virus detection, they
can severely hinder the ability to detect potential non-viral
pathogens or investigate patterns of human gene expression in
response to viral infection, as we have done here.
It has been suggested that co-infections with Streptococcus
pneumoniae may impact the severity of the clinical presentation in
patients infected with 2009 H1N1 [44]. Remarkably, very few co-
pathogens, either viral or bacterial, were found among the 17
samples chosen for analysis. Deep sequencing revealed that only
five samples had a significant number of bacterial reads to the
Streptococcus genus, which may either represent potential pathogens
(e.g. Streptococcus pneumoniae), or simply normal human nasopha-
ryngeal viral flora (e.g. Streptococcus oralis, sanguis, and/or mitis). One
sample from a Canadian patient with an upper respiratory
infection from 2009 H1N1 (BC-22) did contain a small number of
reads from adenovirus type 4 (n=26). These results imply that co-
pathogens did not play a significant role in infection by 2009
H1N1 influenza in the 17 samples analyzed. Further study of a
much larger sample set will be needed to fully ascertain the role of
co-pathogens in 2009 H1N1 infection.
Although 4 of 17 samples contained reads to murine leukemia
viruses, it appears more probable on the basis of sequence
alignments that the source of these reads is trace MMLV vector
contamination of the reverse transcriptase enzyme used in
preparing libraries for deep sequencing rather than infection by
XMRV, a gammaretrovirus associated with prostate cancer and
chronic fatigue syndrome in humans [39,40] and recently detected
in the respiratory tract [38]. In addition, one sample (BC-22)
contained a paired-end read of 97 nt that was a 98% match to the
filovirus Ebola-Sudan. We considered this most likely a laboratory
contaminant, since we did not identify any other reads to
filoviruses and were unable to amplify additional filovirus sequence
from BC-22. However, the origin of this sequence ultimately
remains unknown, as we could not subsequently detect it in any
sample or reagent by specific RT-PCR, and none of the
laboratories involved in the analysis works with Ebola virus. We
also found reads corresponding to plant viruses in two samples
(BC-76 and Mex-1225). Detection of plant viruses in nasal swab
samples is not unexpected given that the nasopharynx is
contiguous with the oropharynx, and that an abundance of plant
viruses of presumed dietary origin can be found in the human
digestive tract [45]. Our discovery of unexpected viral reads
corresponding to murine leukemia viruses, filoviruses, and plant
viruses in the deep sequencing data underscores the challenges of
analyzing rare or unique sequences that may correspond to
colonizing flora, reagent/sample contamination, or even true
pathogens.
Using deep sequencing, we were able to recover and assemble
near full-length genome sequences of the 2009 H1N1 virus from
two individual patient specimens. Since the molecular determi-
nants of influenza pathogenesis have been well-studied, we were
able to analyze the genomic sequence for single nucleotide
polymorphisms (SNPs) that specifically correlate with antiviral
resistance, enhanced transmission or increased virulence. For a
novel virus, where such genotypic findings would not yet be
correlated with phenotypic data, the overall sequence and
structure of the genome may still yield valuable insights into viral
transmission and mechanisms of pathogenesis.
Analysis of transcriptome reads demonstrated that immunity
and interferon genes were significantly up-regulated in 4
nasopharyngeal swab samples from 2009 H1N1-infected patients
as compared to background controls. Interestingly, these 4
samples did not necessarily have a high number of transcriptome
reads, but did have the highest 1X coverage of the influenza
genome (Fig. 7B). Coverage of the influenza genome may be the
best proxy measure for influenza activity and the associated host
response in deep sequencing analysis, as it is relatively
independent of PCR duplication artifacts that can be introduced
during sample preparation for deep sequencing [46]. Our finding
of increased expression of interferon-associated host genes in
clinical samples from patients with 2009 H1N1 infection is
intriguing and consistent with very recent data showing that the
NS1 protein of 2009 H1N1 lacks the ability to block general host
gene expression in both human and swine cells in vitro [47].
Further studies are needed to assess the clinical relevance of
increased interferon-associated host gene expression in 2009
H1N1 infection in vivo. Nevertheless, this finding highlights the
power of an unbiased deep sequencing approach by not only
facilitating detection of the viral pathogen but also enabling
elements of the host response to be simultaneously interrogated,
thus generating new hypotheses for analysis of host-pathogen
interactions.
Our study is the first to explore the relationship between viral
titer and depth of sequencing required to detect a candidate viral
pathogen. In samples that are treated with DNase after nucleic
acid extraction (‘‘post-DNAse’’), there is a linear correlation
between percentage of viral reads in the deep sequencing data and
viral titers as estimated by quantitative RT-PCR (Fig. 5A). There
is no such observed correlation if samples do not undergo post-
DNAse treatment, likely secondary to high residual host genomic
background, and thus these findings may only apply to RNA viral
targets. However, it is encouraging that sequence reads corre-
sponding to 2009 H1N1 were detectable in all 17 samples, even in
those samples with very low viral titers approaching the analytical
limits of detection for RT-PCR assays (i.e. Cal-UC12 and BC-59)
(Fig. 5B).
More studies are clearly needed on the metagenomics of
different viral agents (e.g. RNA vs. DNA viruses; lysogenic vs.
lytic, etc.) across different stages of infection (e.g. pre-symptom-
atic, acute, or chronic) and in different types of clinical samples
( e . g .r e s p i r a t o r ys e c r e t i o n s ,s t o o l ,b l o o d ,c e r e b r o s p i n a lf l u i d ,t i s s u e
etc.). In addition, although the Virochip microarray has a 12 to 24
hour turnaround time and can be rapidly deployed as a
comprehensive screen for viral pathogens in the setting of
outbreaks, the complementary deep sequencing approach is
currently limited by the time necessary to perform a full paired-
end sequencing run on an Illumina Genetic Analyzer IIx (,1
week) and to analyze the data on a highly parallel computational
platform running 32 cores simultaneously (,1 week). Neverthe-
less, the data that can be obtained in days to weeks by microarrays
and deep sequencing would take months to years using
conventional methods. Furthermore, third-generation sequencing
technologies which can generate deep sequencing data within
hours are now available [48,49]. The results described here
provide a blueprint for the eventual use of microarrays and
sequencing as routine diagnostic tools for pathogens in clinical
and public health laboratories.
Metagenomics of 2009 H1N1 Flu
PLoS ONE | www.plosone.org 12 October 2010 | Volume 5 | Issue 10 | e13381Methods
Ethics statement
Cases of influenza-like illness in Canada and Mexico that were
confirmed or suspected positive for 2009 H1N1 infection were
identified by each individual state public health agency. Informed
consent was not obtained as the analysis of samples for pathogens
is part of the mandate of clinical testing for each individual agency,
and samples as well as demographic, clinical, and laboratory data
were de-identified prior to analysis. Cases in California were
enrolled in a viral diagnostics study approved by the University of
California, San Francisco (UCSF) institutional review board (IRB)
(Protocol #H9187-32565), and written informed consent was
obtained from all study participants and/or their legal guardians.
For all cases, collected samples were analyzed under protocols
approved by the UCSF IRB (Protocol #H49187-32368).
Sample identification and collection
Cases of influenza-like illness in Canada and Mexico were
reported by providers and hospitals to the British Columbia
Centre for Disease Control (BC-CDC), the University of Toronto/
Ontario Agency for Health Protection and Promotion (OAHPP),
and the Veracruz Ministry of Health. Suspected or confirmed
H1N1 cases were identified through routine laboratory surveil-
lance under protocols approved by each individual state public
health agency. For each case, non-identifying demographic and
clinical data were reported on standardized forms. Cases in
California were identified by infectious disease physicians at
University of California at San Francisco (UCSF), and demo-
graphic/clinical data were abstracted from the medical record.
Sample analysis
Nasopharyngeal swab samples collected in viral transport media
from 17 patients with either laboratory-confirmed or suspected
cases of 2009 H1N1 influenza virus were analyzed. Twelve
additional nasopharyngeal swab samples from California were
included as negative controls for the Virochip. RNA extractions
were performed differently using established protocols specific to
individual laboratories. For Mexico, 200 mL of sample with linear
polyacrylamide (Ambion, Inc., Austin, TX) added as an RNA
carrier was treated with Turbo DNase (Ambion, Inc., Austin, TX))
for 30 minutes at 37uC (‘‘pre-DNase’’ treatment); nucleic acid was
then extracted using the PureLink RNA-DNA kit (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. For
British Columbia and Ontario, 200 mL and 250 mL, respectively,
of sample were extracted using the NucliSENS easyMag
automated extraction system and then treated with Turbo DNase
(‘‘post-DNase’’ treatment). For California, 200 mL of sample was
treated with Turbo DNase, nucleic acid was extracted with the
Zymo Viral RNA kit (Zymo Research, Orange, CA), and then the
extracted nucleic acid was treated again with Turbo DNase
(‘‘pre-/post-DNase’’ treatment).
Microarray screening
Total RNA was reverse-transcribed to cDNA, amplified by a
modified Round A/B random PCR method, and labeled with Cy3
or Cy5 fluorescent dye as previously described [7,8]. The labeled
samples were normalized to 10 pmol of incorporated dye and
hybridized overnight using the Agilent Gene Expression Hybrid-
ization kit according to the manufacturer’s protocol (Agilent
Technologies, Santa Clara, California). The microarray slides used
were custom-designed 8615k or 8660k arrays synthesized by
Agilent Technologies, each containing 11,956 Virochip 70-mer
oligonucleotide probes in common. These 11,956 common probes
include conserved as well as specific probes representing all viral
species in GenBank, and were derived from a previous 2008
Virochip design [12]. The Virochip is not yet commercially
available, but is currently implemented as a core diagnostic service
of the UCSF Viral Diagnostics and Discovery Center (http://
vddc.ucsf.edu). Slides were scanned at 2 mm resolution in XDR
(extended dynamic range) mode using an Agilent DNA Micro-
array Scanner. Virochip microarrays were analyzed with hierar-
chical cluster analysis, E-Predict, and Z-score single oligonucleo-
tide analysis as previously described [7,11,35]. Average
normalized microarray intensities were analyzed using a two-
sample, two-tailed t-test for unequal variances. All Virochip
microarrays used in this study were submitted to the NCBI GEO
database (study accession number GSE24034; microarray acces-
sion numbers GSM591597-591641; microarray design accession
numbers GPL10897 for the 8615k array and GPL10896 for the
8660k array).
PCR and Sanger sequencing
Sequences corresponding to each influenza segment were
obtained by one-step RT-PCR using either a Qiagen One-Step
RT-PCR kit (Qiagen, Valencia, CA) or an Invitrogen Super-
ScriptIII One-Step RT-PCR kit with High Fidelity Platinum Taq
(Invitrogen, Carlsbad, CA), with primers designed based on
conserved terminal and central regions of each segment (Table
S3). Reactions run with the Qiagen kit were done in duplicate to
account for potential polymerase errors. PCR products were run
on a 1.5% agarose gel, and bands of the correct size were cut and
extracted. Fragments were cloned into a pCR2.1 vector (Invitro-
gen, Carlsbad, CA) and Sanger sequenced (Elim Biopharmaceu-
ticals, Hayward, CA) with M13F and M13R primers as well as the
original conserved PCR primers. At least three-fold redundancy
was obtained for each segment. The whole-genome sequences of
2009 H1N1 samples BC-22 and Cal-UC2, including all 8
segments, have been submitted to GenBank (GenBank accession
numbers CY073781-CY073788 for BC-22 and CY073789-
CY073796 for Cal-UC2).
Quantitative RT-PCR
Quantitative RT-PCR for influenza was performed with
primers based on conserved regions in the HA segment, H1N1-
HA-275F (59- GGGAAATCCAGAGTGTGAATCACT-39) and
H1N1-HA-375R (GCTCTCTTAGCTCCTCATAATCGATG-
39) using a Stratagene MX3005P Real-Time PCR system. The
PCR was performed using a Qiagen One-Step RT-PCR kit
(Qiagen, Valencia, CA) in a 12.5 ml reaction containing 3.25 ml
H2O, 2.5 ml 5X PCR buffer, 2.5 ml Q solution, 0.5 ml dNTP,
0.5 ml RT/Taq enzyme mix, 0.75 ml of each primer, 0.25 ml
SYBR Green and 1.5 ml total RNA. Conditions for the PCR were
50uC for 30 min, 95uC for 15 min; 40 cycles of 95uC for 30 s,
50uC for 30 s, and 72uC for 1 min; and a final extension at 72uC
for 7 min. The viral titer was estimated using a standard curve
derived from an in vitro-transcribed and quantified influenza
mRNA standard (data not shown). For the Canadian samples,
viral titers as determined through Ct values were compared with
real-time RT-PCR data obtained independently from reference
laboratories in Vancouver (BC-CDC) and Toronto (OAHPP) to
check for accuracy (data not shown).
Deep sequencing library generation
Libraries for deep sequencing were prepared from amplified
cDNA libraries using previously published protocols [50]. Briefly,
libraries were cleaved with Type IIs restriction endonucleases
(GsuI), and truncated adapters containing unique 3 or 6 bp
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length adapters were subsequently added via an additional 15 to
25 cycles of PCR. Libraries were size-selected on a 4%
polyacrylamide gel at approximately 350 bp average length, and
then loaded at a final concentration of 10 pM on three lanes of a
second-generation Genome Analyzer IIx (Illumina, San Diego,
CA). Paired-end reads were sequenced for 67 cycles in each
direction.
Deep sequencing analysis
Fluorescent images were analyzed using the Illumina base-
calling pipeline 1.5.0 to obtain paired-end sequencing data.
Paired-end reads were subsequently classified by strict barcodes,
filtered to eliminate low-complexity sequences with an LZW
compression ratio cutoff of 0.4, split into individual reads, and
stripped of any remaining primer sequences using BLASTN
alignments (word size =11, E-value =1610
210). BLASTN
alignments to publicly available sequence databases were per-
formed using four ExtraLarge High CPU-instance Amazon Elastic
Cloud Computing (EC2) servers comprising a total of 32 core
processors, with an approximate computational time of 24 hours per
sequencing lane. Sequence reads that aligned to human rRNA and
mitochondrial genome by BLASTN (word size =11, E-value =
1610
10) were initially removed. Remaining reads were then
classified by successive BLASTN alignments to the RefSeq human
transcriptome database (word size =11, E-value =1610
210,
September 2009 build [release 37]) and NCBI non-redundant
nucleotide (NT) database (word size =11, E-value =1610
25,
March 2010 build). All reads that aligned to NT were sorted by
their best hit into their respective taxa for analysis. Reads that
aligned to NT but that did not align to human, bacterial, or viral
sequences were categorized as ‘‘other’’, and consisted solely of
environmental sequences or plasmids/artificial constructs. The
presence of murine leukemia virus and Ebola virus in the deep
sequencing libraries was independently confirmed by specific RT-
PCR and direct sequencing (data not shown). We also separately
performed directed BLASTN alignments of the original set of
unclassified deep sequencing reads to an influenza sequence
database (word size =11, E-value =1610
25) to verify that
no influenza reads were incorrectly classified as human or other
nonviral sequence (data not shown). All high-quality sequence
reads have been submitted to the NCBI Sequence Read
Archive (http://www.ncbi.nlm.nih.gov/sra) (accession number
SRA023755).
Transcriptome analysis
Reads corresponding to the human mRNA transcriptome were
counted by gene and compared to transcriptome reads from
nasopharyngeal swab samples from Kleine-Levin syndrome (KLS)
patients with influenza-like illness. KLS is a neuropsychological
disorder marked by hypersomnolence, hyperphagia, and hyper-
sexuality usually found in adolescent boys [51]. An ongoing
metagenomic analysis of samples from 11 patients with KLS
(‘‘KLS samples’’) by deep sequencing found only 24 reads to a
single rhinovirus A isolate in one sample and no reads to influenza
in any sample; in addition, all KLS samples were negative for both
pandemic and seasonal influenza by specific RT-PCR (data not
shown). As such, it was thought that the KLS samples could serve
as appropriate background controls from individuals with
influenza-like illness (but testing negative for influenza) for the
purposes of transcriptomic analysis. In particular, the KLS
samples were derived from a similar demographic as the H1N1
samples (children and young adults) and were processed identically
for deep sequencing.
The transcriptomic analysis was performed as follows. First, we
selected all genes in RefSeq that were significantly overexpressed
in 2009 H1N1 nasopharyngeal swab samples relative to KLS
background samples (p,0.05, by Bonferroni-corrected Fisher’s
Exact Test). To identify overrepresented categories of genes, we
inputted the overexpressed RefSeq genes into the PANTHER
(Protein Analysis Through Evolutionary Relations) database
(http://panther.appliedbiosystems.com) and compared them to a
human reference list of transcribed genes [52]. Categories of genes
significantly up-regulated in the influenza data relative to the
human reference list (p,0.05, by Bonferroni-corrected Fisher’s
Exact Test) were reported.
Detection of single nucleotide polymorphisms (SNPs)
SNP analysis of sequence reads mapping to influenza was
performed using the SSAHA2 software package [53]. Both paired-
end read information and FASTQ-formatted quality scores were
incorporated in the calling of SNPs. SNP calling was performed at
very high stringency to ensure accuracy. Specifically, the Illumina
deep sequencing data had a calculated overall error rate of ,1%
by analysis of the PhiX control lane (Illumina Inc., Hayward, CA),
and at least 5-fold coverage and a quality score of 30 were required
for mapping of deep sequencing reads at any given position in the
genome. A minority SNP was defined as present if occurring
$25% of the time at a given nucleotide position.
Paired-end de novo sequence assembly
Paired-end de novo assembly of the influenza genome was
performed using Geneious version 5.0.1 software [54], with strict
parameters (word length =18; 0% mismatch/gap tolerance; only
paired-end reads included in assembly; expected paired-end mate
distance=200) to avoid misassembly, The de novo assembly
algorithm used by Geneious is a greedy algorithm similar to that
used in multiple sequence alignment programs such as ClustalW
(Matt Kearse, Geneious Inc., personal communication) [55].
Initial generated contigs of size $100 bp were further assembled
de novo in Geneious at high sensitivity with ‘‘fine tuning’’ of
gaps and 3-nt trimming of contig ends. Final de novo assembled
contigs were then mapped to the full-genome reference sequence
A/California/06/2009(H1N1) (GenBank accession numbers
FJ966960 – FJ966965 and FJ971074-FJ971075). Out of the
remaining 561 contigs that did not map to influenza, ,90% of
the contigs corresponded to low-complexity sequence that was
identified as such by applying an LZW compression ratio of 0.5,
slightly higher than that used in the initial filtering (0.4).
Supporting Information
Figure S1 Coverage map of the influenza genome for 2009
H1N1 samples from Canada. The coverage is plotted on a log
scale as a function of nucleotide position.
Found at: doi:10.1371/journal.pone.0013381.s001 (0.96 MB
EPS)
Figure S2 Coverage map of the influenza genome for 2009
H1N1 samples from California and Mexico. The coverage is
plotted on a log scale as a function of nucleotide position.
Found at: doi:10.1371/journal.pone.0013381.s002 (0.92 MB EPS)
Table S1 Study patients with 2009 H1N1 influenza (n=17).
Found at: doi:10.1371/journal.pone.0013381.s003 (0.07 MB
XLS)
Table S2 2009 H1N1 single nucleotide polymorphisms in
samples Cal-UC2 and BC-22. Nonambiguous SNPs in samples
Cal-UC2 and BC-22 were determined by alignment to the A/
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position is based on the A/California/04/2009 reference
sequence.
Found at: doi:10.1371/journal.pone.0013381.s004 (0.07 MB
XLS)
Table S3 Primers used for whole-genome Sanger sequencing of
2009 H1N1 samples BC-22 and Cal-UC2.
Found at: doi:10.1371/journal.pone.0013381.s005 (0.05 MB
XLS)
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